As the treatments for breast cancer improve,disease free survival time is extensively prolonged and pharmaceutical developer faces a new challenge in clinical trial design and conduct based on long te
In the early phase development of molecularly targeted agents(MTAs),a commonly encountered situation is that the MTA is expected to be more effective for a certain biomarker subgroup,say marker-positi